CGEN
CompugenNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$235.53M
P/E Ratio
6.53
EPS
$0.38
Beta
2.77
52W High
$2.49
52W Low
$1.23
50-Day MA
$1.97
200-Day MA
$1.70
Dividend Yield
—
Profit Margin
48.60%
Forward P/E
12.36
PEG Ratio
1.29
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Fundamentals
| Revenue (TTM) | $72.76M |
| Gross Profit (TTM) | $63.51M |
| EBITDA | $31.80M |
| Operating Margin | 83.20% |
| Return on Equity | 44.80% |
| Return on Assets | 14.40% |
| Revenue/Share (TTM) | $0.78 |
| Book Value | $1.09 |
| Price-to-Book | 2.11 |
| Price-to-Sales (TTM) | 3.24 |
| EV/Revenue | 0.925 |
| EV/EBITDA | 2.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 4477.00% |
| Shares Outstanding | $94.55M |
| Float | $92.41M |
| % Insiders | 2.08% |
| % Institutions | 13.52% |
Historical Volatility
HV 10-Day
56.62%
HV 20-Day
47.61%
HV 30-Day
86.44%
HV 60-Day
77.52%
HV Rank
82.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.83 target)
5
BuyData last updated: 4/10/2026